|
Patent landscape, scope, and claims: |
United States Patent 11,779,552: scope, claim-by-claim coverage, and US patent landscape for treating aromatase-inhibitor-resistant ER+ breast cancer with (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino}-4-methoxyphenyll-5,6,7,8-tetrahydronaphthalen-2-ol
Executive summary
- US 11,779,552 is a method-of-use patent that claims treating estrogen receptor (ER)-positive breast cancer resistant to aromatase inhibitors by administering a single, specifically named stereodefined compound: (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino}-4-methoxyphenyll-5,6,7,8-tetrahydronaphthalen-2-ol}.
- The asserted claim scope is driven by three claim anchors: (1) patient phenotype (ER+ and aromatase-inhibitor resistant), (2) use of the specific compound (R-enantiomer with the enumerated chemical identity), and (3) combination permissiveness (claims 12-14 allow broad co-therapy classes, including CDK4/6 inhibitors and antiestrogens).
- The dependent claims expand coverage across formulation and administration variables (composition; daily single-dose or multi-dose; route including oral and parenteral) and across aromatase inhibitors (explicit list).
What is US Patent 11,779,552 claiming: method for ER+ aromatase-inhibitor-resistant breast cancer with a specific (R)-compound?
Answer (scope in one line): US 11,779,552 claims a therapeutic method for ER+ breast cancer that is resistant to one or more aromatase inhibitors, using the R-stereoisomer of a specific small molecule with the chemical structure recited in claim 1.
Claim 1 is the only independent claim and controls the estate’s boundary
You provided the full independent claim language for claim 1. Key scope elements that define infringement and invalidate off-target variants:
-
Indication / patient selection
- “an estrogen receptor positive breast cancer in a subject”
- “resistant to one or more aromatase inhibitors”
- This pairs a biomarker and a treatment-resistance criterion. Practically, the claim targets patients whose disease progressed on or after aromatase inhibitor therapy, or otherwise meets a recognized resistance phenotype.
-
Drug identity
- Administration of “a compound, (R)-6-{…}-5,6,7,8-tetrahydronaphthalen-2-ol”
- The compound is stereochemically specified as (R).
- The scope is therefore not “a class of compounds,” but a use of a particular chemical (even if other related structures exist in the portfolio).
-
Therapeutic intent
- “method of treating”
- The claim is not a pharmacokinetic claim, not a formulation claim, and not a manufacturing method claim.
How resistance language is likely to function in enforcement
- The claim requires resistance to one or more aromatase inhibitors. In litigation, that typically means the accused patient group must be classified as having aromatase inhibitor-resistant disease by clinical history and standard definitions used in the art.
- The explicit aromatase inhibitor list in dependent claim 5 narrows which aromatase inhibitors qualify, but the independent claim already says “one or more aromatase inhibitors.” Dependent claim 5 helps plaintiffs argue that the “resistant to one or more” element is satisfied when resistance is tied to named drugs.
What are the claim-by-claim limits and expansion points in US 11,779,552?
Claim chart (US 11,779,552 as provided)
| Claim |
What it adds |
Scope effect (what it captures / what it excludes) |
| 1 |
Independent method: ER+ breast cancer resistant to aromatase inhibitors; administer the specific (R)-compound |
Core infringement boundary. Requires all elements: indication, resistance phenotype, and compound identity. |
| 2 |
“administered as part of a pharmaceutical composition” |
Adds a formulation element. If a product is administered as a finished dosage form, this stays met; if pure API is administered, claim 2 might still be met depending on whether that is “part of a pharmaceutical composition.” |
| 3 |
composition administered “daily as a single dose” |
Adds dosing regimen granularity. Single daily dose product or regimen meets this. |
| 4 |
composition administered “daily as a multi-dose” |
Captures split-dose regimens while staying within “daily.” |
| 5 |
aromatase inhibitor(s) are selected from enumerated list |
Narrows the “one or more” aromatase inhibitors to the listed drugs. If the accused therapy is tied to a listed aromatase inhibitor, claim 5 fits cleanly. |
| 6 |
aromatase inhibitor(s) selected from anastrozole, letrozole, exemestane, and combinations |
Further narrows to three common AI therapies (plus combos). |
| 7 |
“effective amount” |
Introduces dose concept without a specific numerical range. Keeps flexibility for different dose levels that are still “effective.” |
| 8 |
effective amount “from about 200 mg/day to about 500 mg/day” |
Tightens dose range and strengthens enforcement for products in that bracket. |
| 9 |
effective amount “about 400 mg/day” |
Single-point anchor dose for a typical pivotal dose. Useful for proving willful infringement if the accused product uses ~400 mg/day. |
| 10 |
routes: oral, IV, intradermal, IM, subcutaneous |
Very broad routes. Route switching by an accused infringer is unlikely to avoid claim 1/7, unless route is outside listed options. |
| 11 |
“wherein … oral administration” |
Locks coverage on oral regimens. |
| 12 |
combination: add at least one compound selected from broad therapeutic classes |
Expands method to combo regimens. Broad enough to include most mainstream breast cancer combination strategies. |
| 13 |
combo specifically “CDK4/6 inhibitor” |
Narrows class and targets common ER+ regimen partners (palbociclib, ribociclib, abemaciclib). |
| 14 |
combo specifically “antiestrogen” |
Covers antiestrogen partners (e.g., fulvestrant, SERDs/SERMs depending on how construed). |
Practical scope read-through
- A generic or competitor trying to design around by using the same “(R)-compound” but with a different indication or phenotype likely hits the indication + resistance limitation.
- A design-around that switches to a different enantiomer (S) would likely avoid exact literal identity if the claim language is enforced strictly as written, because claim 1 explicitly requires (R).
- A design-around that uses the same compound but excludes aromatase inhibitor resistance patients may still risk doctrine-of-equivalents arguments depending on the record, but the claim text is phenotype-anchored.
Which aromatase inhibitors are covered by US 11,779,552 and how do claims 5 and 6 change infringement?
Claim 5 AI list
Claim 5 lists: anastrozole, letrozole, exemestane, formestane, fadrozole, aminoglutethimide, testolactone, and combinations.
Impact: If the accused regimen is positioned as treatment of AI-resistant disease where resistance is tied to any one or more of these AIs, claim 5 is a strong fit for enforcement.
Claim 6 tighter AI subset
Claim 6 limits to: anastrozole, letrozole, exemestane, and combinations.
Impact: Claim 6 supports narrower arguments where the clinical history centers on the most common AIs.
What dosage and administration methods are protected by US 11,779,552?
Dose range protection (claims 7-9)
- Claim 7: “effective amount”
- Claim 8: “about 200 mg/day to about 500 mg/day”
- Claim 9: “about 400 mg/day”
Enforcement leverage:
- If the accused regimen is dosed in the mid-range, claims 8 and 9 materially strengthen the “effective amount” proof with numerical boundaries.
- If a party doses outside the range, they may still try to argue “effective amount” under claim 7, but that becomes fact- and evidence-heavy.
Route coverage (claims 10-11)
- Claim 10 includes: oral, IV, intradermal, IM, subcutaneous
- Claim 11 isolates oral administration
Design-around by route is unlikely to work because claim 10 covers multiple delivery modes. Only routes not among the listed ones would create a straightforward literal-avoidance path.
Dosing frequency (claims 3-4)
- Claim 3: daily single dose
- Claim 4: daily multi-dose
Design-around by schedule would require adopting a regimen not meeting the “daily” and “single vs multi” constructs as construed in the litigation record.
What combination therapies are allowed under the claims of US 11,779,552?
Claim 12 broad combination partners
Claim 12 permits administering the claimed (R)-compound with at least one additional agent from:
- CDK4/6 inhibitor
- antiestrogen
- ligand of retinoic acid or retinoxic X receptor
- antiprogestin
- antiandrogen
- vitamin D or metabolite thereof
- farnesyl transferase inhibitor
- PPARα or gamma agonist
- MAP kinase inhibitor
Scope effect: The claim is not limited to monotherapy. It is written to capture real-world combination practice and to reduce the risk that a competitor positions its regimen as “combination” rather than “monotherapy.”
Claims 13-14 narrow the combination anchors
- Claim 13: CDK4/6 inhibitor
- Claim 14: antiestrogen
This creates litigation-ready hooks for common ER+ breast cancer combination standards.
How strong is the US 11,779,552 patent estate likely to be based on claim structure alone?
High-level strength indicators from your provided claims:
- Narrow drug identity (specific (R)-compound) typically improves enforceability versus functional claim language, because the accused product can be directly compared.
- Clear indication phenotype (ER+ and AI resistance) improves specificity and can help distinguish from earlier general ER+ treatments.
- Broad regimen latitude (routes; combo partner classes) reduces design-around space by competitors.
- Numerical dose range (200–500 mg/day and “about 400 mg/day”) adds evidentiary traction for infringement analysis of dose-matched products.
Weakness indicators that matter for litigation posture:
- Because this is a method-of-use claim, infringement proof depends on how the accused product is used in practice (patient selection, clinical history of AI resistance, dosing and regimen). That is often manageable but can become a record-intensive question.
- The stereochemical requirement can be a double-edged sword: it is strong if the accused drug is truly not the (R) enantiomer, but it can narrow enforcement if the accused formulation uses a mixture that includes (R). Courts will treat mixture composition questions based on chemical identity and proof.
Where does US 11,779,552 sit in a broader US breast cancer IP landscape for ER+ and AI-resistant disease?
Even without additional document metadata (publication number, assignee, filing/priority chain, or related family members), your provided claim set indicates US 11,779,552 is designed to sit at the intersection of:
- ER+ breast cancer therapeutics (method-of-treatment framework)
- aromatase inhibitor-resistant patient subsets
- combination oncology standards via CDK4/6 and antiestrogens, plus other targeted classes
This kind of claim is typically built to cover:
- a monotherapy regimen and
- a combination regimen that would occur in routine clinical practice.
Competitive risk implication: If any competitor product uses the same (R)-compound in the same AI-resistant ER+ population, with overlapping dosing and routes, it faces straightforward literal exposure under claim 1 and its dependent scaffolding.
What patent landscape features should be analyzed alongside US 11,779,552 for licensing or generic entry risk?
Because your request is for “scope and claims and patent landscape,” the landscape analysis for real-world decisioning usually triangulates three layers:
- Core compound identity patents
- The moment a method patent ties to a specific compound, freedom-to-operate depends on whether a separate compound composition or substance patent blocks manufacture or sale.
- Formulation and dosing regimen patents
- Claims 2-4 and 7-9 show the estate is also designed to cover typical regimen choices. Separate formulation patents may exist in the family.
- Combination claim coverage
- Claim 12 is broad. In real practice, combination products can multiply exposure because multiple partners are used with the same base agent.
For licensing, the critical question is whether the method-of-use claim alone can block clinical use, or whether other patents (drug substance, polymorph, salt forms, manufacturing) also block commercial supply.
Key Takeaways
- US 11,779,552 is centered on treating ER+ aromatase-inhibitor-resistant breast cancer by administering a specific (R)-enantiomer small molecule with the structure recited in claim 1.
- Claim 1 sets the boundary: ER+ + AI resistance + the (R)-compound.
- Dependent claims materially expand practical coverage across pharmaceutical composition, daily dosing schedules, dose levels (200–500 mg/day; ~400 mg/day), multiple routes (including oral), and combination regimens (notably CDK4/6 inhibitors and antiestrogens).
- The claim set is structured to reduce design-around options by covering routes, regimens, and combination partners while keeping literal drug identity tightly defined.
FAQs
Does US 11,779,552 cover monotherapy or only combination regimens?
It covers monotherapy under claim 1. Claims 12-14 cover combination regimens by adding specified co-therapies.
Can a competitor avoid infringement by changing the route of administration?
Claim 10 already covers oral, IV, intradermal, IM, and subcutaneous, so route changes among those options do not avoid coverage. Only routes outside the listed set could create a literal gap.
What dose levels are specifically protected under US 11,779,552?
The claims protect an “effective amount” and specifically recite about 200 mg/day to about 500 mg/day (claim 8) and about 400 mg/day (claim 9).
Which CDK4/6 and antiestrogen partners are implicated by the combination claims?
Claim 13 covers a CDK4/6 inhibitor generally; claim 14 covers an antiestrogen generally. Specific agents are not enumerated in the provided claim text.
Is the aromatase inhibitor scope broader in claim 1 or constrained in later claims?
Claim 1 covers “one or more aromatase inhibitors” generally, while claims 5-6 constrain to enumerated AIs, with claim 6 limited to anastrozole, letrozole, exemestane (and combinations).
References
- United States Patent 11,779,552 (claims as provided by user).
More… ↓
⤷ Start Trial
|
